Oncimmune Holdings PLC Appointment of Non-Executive Director (5860M)
January 13 2023 - 2:00AM
UK Regulatory
TIDMONC
RNS Number : 5860M
Oncimmune Holdings PLC
13 January 2023
13 January 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of Non-Executive Director
Oncimmune Holdings plc (AIM: ONC.L), a leading global
immunodiagnostics group, is pleased to announce that further to the
announcement made on 7 December 2022, John Goold has been appointed
to the Board of the Company as Non-Executive Director with
immediate effect, following the successful completion of customary
due diligence checks by the Company's Nominated Adviser.
Additional Information in respect of the AIM Rules
The following information regarding the appointment of John
Howard Goold, aged 51, is disclosed under Schedule 2(g) of the AIM
Rules for Companies:
Current Directorships Previous Directorships (within
the last five years)
Freelands Finance Limited Zeus Capital Limited
Kelso Group Holdings plc Zeus Group Limited
Kelso Ltd Zeus Securities Limited
Zeus Capital Investment Limited
---------------------------------
As at the date of this announcement, John Goold holds 1,150,000
ordinary shares in the Company equivalent to 1.55% of the Company's
issued share capital.
Save as set out above there are no further disclosures pursuant
to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies in respect of the appointment of John Goold.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser, Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. The ImmunoINSIGHTS service
business leverages Oncimmune's technology platform and
methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the
development and product lifecycle. Our core immune-profiling
technology is underpinned by our library of over eight thousand
immunogenic proteins, one of the largest of its kind. This helps
identify trial participants and patients into clinically relevant
subgroups, enabling development of targeted and more effective
treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the
Company's discovery research centre in Dortmund, Germany. The
business platform enables life science organizations to optimize
drug development and delivery, leading to more effectively targeted
and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and
Europe and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
EarlyCDT Product Business
Oncimmune's immunodiagnostic technology, EarlyCDT(R), can detect
and help identify cancer on average four years earlier than
standard clinical diagnosis. Our lead diagnostic test, EarlyCDT(R)
Lung, targets a vast market estimated to grow to GBP3.8bn by 2024.
With over 200,000 tests already performed for patients worldwide
and its use being supported by peer reviewed data in over 12,000
patients, we are poised to become an integral component of future
lung cancer detection programs, globally.
Oncimmune's diagnostic products business is located at its
laboratory facility in Nottingham, UK.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLGDBCGBDGXD
(END) Dow Jones Newswires
January 13, 2023 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024